R&D Published on October 15, 2019 Researchers at Polytechnique Montréal and IBM Zurich have found a way to “bend” drops of liquid to prevent them from dispersing. Their discovery was published in the prestigious journal Nature (french content) Read more
Business environment Published on October 15, 2019 The recipients of the Sciences & Research “Prix du Québec 2019” are now known! (french content) Read more
Artificial Intelligence Published on October 15, 2019 Join Jumio on October 18th for cocktails and hors d’oeuvres, networking with international ML professionals, and Q&A with Jumio AI engineers. Read more
Manufacturing Published on October 9, 2019 Silicycle, a Quebec company, is about to market a cartridge, the SiliaMetS E-PAK, which allows pharmaceutical companies to more efficiently remove metals used in the drug manufacturing process. (french content) Read more
Business environment Published on October 9, 2019 CQIB Life Sciences Incubation Program Generates More Than $ 350 Million Investment (french content) Read more
Pharma Published on October 7, 2019 Theratechnologies Inc. is pleased to announce that the Canadian Cancer Society and the Government of Quebec, through the Consortium Québécois sur la découverte du médicament (CQDM), will contribute to a grant totaling 1.7 million dollars to l’Université du Québec à Montréal (UQAM) as part of the overall investment made by Theratechnologies towards the development of its targeted oncology platform. Read more
Business environment Published on October 7, 2019 Prometic Life Sciences Inc. announced results from the special meeting of shareholders held in Montreal. Shareholders representing approximatively 87% of votes cast approved a special resolution authorizing the Company to amend its articles to change its name to Liminal BioSciences Inc. Read more
Pharma Published on October 7, 2019 Milestone Pharmaceuticals Inc., a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, announced that the first patient has been enrolled in the Phase 3 NODE-303 study. NODE-303 is the Company’s open-label, global safety study of etripamil, the Company’s novel, potent and short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT). Read more
Published on October 1, 2019 NEOMED-LABS, Pacific Biomarkers and PAIRimmune announcing Nexelis, a new name with long experience in the world of immuno-science. Read more